Factual background
7 In about May 2011, Biomax, as principal, entered into an agency agreement with Jabiru as agent. Relevantly, the agency agreement set sales targets for Jabiru to achieve as Biomax' agent in the sale and exploitation of Biomax' rapid thermophilic digestion technology and machines. Biomax marketed rapid thermophilic digestion machines that were capable of processing waste product from agricultural activities and converting that to material that could be used to provide nutrients and other substances to assist in agricultural and farming activities. Clause 4.1 of the agency agreement set a sales target for the 2012 year of USD3 million.
8 Biomax could terminate the agency agreement by giving Jabiru seven days written notice if Jabiru had failed to achieve an annual agreed sales target (cl 6.1.3). Clause 6.2 required Jabiru to return promptly to Biomax all property belonging to it in accordance with its directions and to cease to promote, market, advertise or sell Biomax' goods, to maintain its confidentiality undertaking in cl 11, and to continue to provide an indemnity under cl 17.
9 The agency agreement also provided in cl 7.1 that, during its term, Jabiru had to act in the interests of Biomax, not allow Jabiru's interests to conflict with the duties that it owed to Biomax and to act towards Biomax dutifully and in good faith. During the term of the agreement and for one year after its termination, Jabiru agreed not to directly or indirectly sell, offer to sell, negotiate the sale or be concerned with or interested in, relevantly, the promotion or marketing of any goods that were similar to Biomax' goods or which competed with it, without first obtaining Biomax' consent (cl 7.4). Jabiru also agreed not to represent or sell products similar to those presently manufactured by Biomax or to financially support, directly or indirectly, any competitive organisation (cl 7.5). Jabiru was not authorised to enter into any compromise or agreement with any of Biomax' customers (cl 7.9).
10 The agreement also placed constraints on Jabiru's ability to use Biomax' intellectual property rights and literature except in the course of its pursuit of the agency on behalf of Biomax. In particular, Jabiru agreed that it was allowed to use the trademarks, copyright and designs in respect of Biomax' goods (which were defined as "intellectual property"), together with literature provided by Biomax in connection with those goods, only as expressly authorised by Biomax (cl 10.1). Jabiru acknowledged that it had no rights to the defined intellectual property and promised not to do, or omit to do, anything by which the goodwill and reputation associated with that intellectual property might be diminished or jeopardised (cl 10.2). Jabiru also acknowledged that Biomax' property included its design of the machines and the formulation of its bacterial enzyme mixes and Jabiru was prohibited from copying the machines or any parts of them or the bacterial enzyme mixes without seeking and obtaining Biomax' permission (cl 10.3). In addition, Jabiru promised promptly and fully to notify Biomax of any actual, threatened, or suspected infringement in Australia of any intellectual property, as defined, that had come to Jabiru's notice (cl 10.4).
11 The amended statement of claim alleged that on 21 November 2011, Ironside purchased a machine from Biomax. Indeed, in its defence Ironside admitted that allegation, as had Jabiru and Mr Beazleigh both in their defence that I struck out and by reason that they now have no defence.
12 On 7 August 2012, the Australian Securities and Investments Commission registered BioComplete Australia Pty Ltd as a company. It was deregistered two years later. Mr and Mrs Beazleigh held 100 shares, or half of its issued capital, and, two companies, Vital Resource Management Pty Ltd and Ironside Management Services Pty Ltd, successively held the balance of 100 shares. Mr Beazleigh was a director of BioComplete from 7 August 2012 to 26 August 2013.
13 On 16 January 2013, Biomax wrote to Jabiru, to Mr Beazleigh's attention, referring to the sales target of USD3 million for the 2012 year and cl 4.1 of the agency agreement, and exercised its right of termination. The letter gave notice to Jabiru of the latter's obligations on termination under cl 6.2.
14 Biomax seeks declarations that in the period between the incorporation of BioComplete and the termination of the agency agreement on 16 January 2013, Jabiru had breached that agreement and that Mr Beazleigh was a party to, knowingly concerned in, or had induced those breaches by Jabiru.
15 I am satisfied by Mr Wibowo's evidence that Biomax owned the copyright in a number of photographs being images 1, 2, 8, 9, 10 and 11 together with a diagram of a machine that is image 12 set out in schedule 1 to the orders that I will make today. Based on Mr Wibowo's evidence I find that each of the images had been created by persons acting for, and the copyright in them became the property of, Biomax at times that preceded the termination of the agency agreement on 16 January 2013.
16 The amended statement of claim alleged that, from about 7 August 2012, BioComplete had infringed Biomax' copyright in the images by reproducing, in a material form, the whole, or a substantial part, of them on BioComplete's website at www.biocomplete.com.au, communicating the whole, or a substantial part, of those copyright works to the public using that website and in reproducing, in a material form, the whole, or a substantial part, of those copyright works in BioComplete's marketing material for its competing products.
17 Mr Wibowo accessed BioComplete's webpage on 28 May 2013 and created screen shots of what then appeared on it. The screen shots include each of the images and also substantial parts of some of those images. One instance that demonstrated the flagrancy of BioComplete's infringement of Biomax' copyright in the images was BioComplete's reproduction on its webpages of images 1 and 10 where Biomax' logo appeared, albeit more clearly in image 1. Image 1 was completely reproduced in the middle of BioComplete's webpage headed "Process and Features" including, albeit indistinctly, Biomax' logo, without the editing that had occurred that appears on other screen shots of webpages involving that infringement. In another reproduction of image 1 BioComplete manipulated that photograph on its webpage (which is image 15 in the screen shot exhibit in evidence), that depicted BioComplete's logo appearing in lieu of Biomax' logo.